Contact Us

Contact Us

Please contact us below with any questions

+44 (0)33 3321 2371

Side Contact
COVID-19 Rapid Antigen Lateral Flow Tests in Stock in UK and Available to Buy - More Info
quadratech Logo
{{ toggleHam ? 'CLOSE' : 'MENU' }}
Next Day & International Delivery
Competitive Pricing
Knowledgeable Sales Team
Based In The UK

Article of Interest (Coagulation):Factor Concentrates

Coagulopathy related to massive bleeding has a multifactorial aetiology. Coagulopathy is related to shock and blood loss including consumption of clotting factors and platelets and hemodilution. Additionally hyperfibrinolysis, hypothermia, acidosis, and metabolic changes affect the coagulation system. The aim of any hemostatic therapy is to control bleeding and minimize blood loss and transfusion requirements. Transfusion of allogeneic blood products as well as the presence of coagulopathy cause increased morbidity and mortality.


This paper presents a short review on new treatment strategies of coagulopathy, related to massive blood loss.Paradigms are actively changing and there is still shortage of data. However, there is increasing experience and evidence that “target controlled algorithms” using point-of-care monitoring devices and coagulation factor concentrates are more effective compared to transfusion of fresh frozen plasma, independently of the individual clinical situation.Future treatment of coagulopathy associated with massive bleeding can be based on an individualized point-of-care guided rational use of coagulation factor concentrates such as fibrinogen, prothrombin complex concentrate, and recombinant factor VIIa. The timely and rational use of coagulation factor concentrates may be more efficacious and safer than ratio-driven use of transfusion packages of allogeneic blood products.

Reference:Fries D. Transfusion. 2013 Jan;53 Suppl 1:91S-5S.

Cookie Consent

Cookies help us deliver our services. By using our services, you agree to our use of cookies.